- This topic has 1 reply, 2 voices, and was last updated 1 week, 3 days ago by
.
-
Posts
-
-
-
Warfarin dosing differs significantly between patients because individuals vary in their genetic makeup, drug metabolism, sensitivity to anticoagulation, and clinical characteristics. Even when two patients have the same diagnosis and take the same medication, they may require different doses to achieve the same therapeutic International Normalized Ratio (INR).
Two important genes explain part of this variability: CYP2C9 and VKORC1.
The CYP2C9 gene encodes a liver enzyme responsible for metabolising S-warfarin, the more potent enantiomer of the drug. Certain variants, particularly CYP2C9 *2 and *3, reduce enzyme activity. Individuals carrying these variants may eliminate warfarin more slowly and therefore require lower doses to avoid excessive anticoagulation and bleeding.
The VKORC1 gene encodes vitamin K epoxide reductase, the molecular target of warfarin. This enzyme helps recycle vitamin K, which is required for the production of functional clotting factors II, VII, IX, and X. Genetic variations affecting VKORC1 expression can change sensitivity to warfarin. Some patients require substantially lower doses because their clotting system is more sensitive to the drug, whereas others require higher doses.
However, genetics is only one part of the explanation. Age is important because older adults often require lower doses and may have a higher bleeding risk. Body size, liver function, nutritional status, and vitamin K intake also influence dose requirements. Foods rich in vitamin K, such as spinach, kale, and other leafy green vegetables, can reduce warfarin’s anticoagulant effect when intake changes substantially.
Drug interactions are another major factor. Certain antibiotics, antifungals, anti-inflammatory medicines, and other medications can alter warfarin response or bleeding risk. Acute illness, alcohol intake, poor adherence, and changes in general health may further affect anticoagulation control.
Pharmacogenetic testing can identify relevant variants in CYP2C9 and VKORC1 and combine these findings with clinical information to estimate an appropriate initial dose. Nevertheless, the patient’s response must be assessed using INR monitoring.
In conclusion, differences in warfarin dosing arise from the combined effects of genetic variation, physiological characteristics, diet, medications, and environmental factors. Pharmacogenomics helps explain inherited differences in drug response and supports personalised treatment, but no single gene or genetic test can independently determine the exact warfarin dose for every patient.
-
- You must be logged in to reply to this topic.